Immatics (NASDAQ:IMTX) Rating Increased to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Immatics (NASDAQ:IMTX) from a sell rating to a hold rating in a report released on Monday.

A number of other analysts have also recently issued reports on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Immatics in a research report on Thursday, January 22nd. Mizuho set a $25.00 target price on Immatics in a research report on Thursday, February 19th. Leerink Partners reaffirmed an “outperform” rating and set a $17.00 price target on shares of Immatics in a research note on Thursday, December 4th. Guggenheim lifted their price target on Immatics from $16.00 to $19.00 and gave the company a “buy” rating in a report on Tuesday, November 18th. Finally, Chardan Capital restated a “buy” rating and issued a $25.00 price objective on shares of Immatics in a report on Monday, November 24th. Six analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Immatics has a consensus rating of “Moderate Buy” and a consensus price target of $19.20.

Immatics Stock Up 1.4%

IMTX stock opened at $10.00 on Monday. The company has a 50 day moving average of $9.88 and a two-hundred day moving average of $9.25. The company has a market cap of $1.22 billion, a price-to-earnings ratio of -5.43 and a beta of 1.34. Immatics has a 12-month low of $3.30 and a 12-month high of $12.41.

Immatics (NASDAQ:IMTX) last posted its quarterly earnings results on Thursday, March 5th. The company reported ($0.34) EPS for the quarter, beating the consensus estimate of ($0.48) by $0.14. Immatics had a negative net margin of 411.90% and a negative return on equity of 41.81%. The business had revenue of $23.00 million for the quarter, compared to analysts’ expectations of $12.18 million. On average, research analysts anticipate that Immatics will post -0.72 EPS for the current year.

Institutional Trading of Immatics

Several large investors have recently made changes to their positions in IMTX. Bank of America Corp DE increased its holdings in shares of Immatics by 166.0% during the 4th quarter. Bank of America Corp DE now owns 3,575 shares of the company’s stock valued at $25,000 after acquiring an additional 2,231 shares during the last quarter. Quarry LP bought a new stake in Immatics during the fourth quarter worth approximately $84,000. Insigneo Advisory Services LLC acquired a new position in Immatics during the third quarter valued at approximately $103,000. Engineers Gate Manager LP acquired a new position in Immatics during the second quarter valued at approximately $124,000. Finally, Fox Run Management L.L.C. bought a new position in shares of Immatics in the fourth quarter valued at approximately $129,000. Institutional investors own 64.41% of the company’s stock.

About Immatics

Immatics N.V. (NASDAQ: IMTX) is a clinical-stage biotechnology company dedicated to the development of T cell receptor (TCR)-based immunotherapies for solid tumors. The company leverages its proprietary discovery and engineering platforms to identify tumor-specific peptide targets and develop therapies that harness the power of a patient’s immune system. Immatics’ approach aims to generate durable responses by guiding T cells to recognize and kill cancer cells with high precision.

At the core of Immatics’ technology suite is the XPRESIDENT® platform, which mines the cancer peptidome to uncover novel tumor antigens naturally presented on the surface of cancer cells.